Importing Pharmaceuticals into Switzerland: A Practical Guide
Switzerland is one of the densest pharmaceutical corridors in the world, home to two of the largest drug makers and a cluster of biotech and CROs around Basel, Zurich and Geneva. It is also outside the EU customs union, which means every shipment crosses a real customs border even though Switzerland recognises EU good manufacturing practice. This guide covers who regulates pharmaceutical imports into Switzerland, the licences the Swiss importer needs, how clinical trial material moves, and where shipments most often get held.
Who regulates pharmaceutical imports into Switzerland
Medicinal products in Switzerland are regulated by Swissmedic, the Swiss Agency for Therapeutic Products, under the Therapeutic Products Act. Swissmedic authorises products for the Swiss market, issues the establishment licences that importers and wholesalers must hold, and inspects for good manufacturing and good distribution practice. Customs clearance is handled separately by the Swiss Federal Office for Customs and Border Security, which is moving goods declarations onto its new digital platform, Passar, as it replaces the older e-dec system.
Switzerland is not in the EU or EEA, so goods are formally imported and cleared through Swiss customs. It does, however, have a Mutual Recognition Agreement with the EU covering GMP for medicinal products, so batch certification and inspection outcomes carried out in the EU are generally recognised, and vice versa. That reduces duplicate testing but does not remove the need for the correct Swiss licences.
What the Swiss importer needs
Commercial import of medicinal products into Switzerland is done by an entity established in Switzerland that holds the appropriate Swissmedic establishment licence. The core requirements are:
- A Swissmedic establishment licence covering import and wholesale of the product category being moved.
- Product status. The product is either authorised for the Swiss market, or moves under a defined exemption such as a clinical trial or named-patient supply.
- A Responsible Person for the licensed establishment, accountable for GDP compliance.
- GDP compliance across storage and transport, including temperature control appropriate to the product.
- Customs declaration through the Swiss customs system, with the commercial or proforma invoice, tariff classification and import VAT handled at the border.
| Document | Purpose |
|---|---|
| Commercial or proforma invoice | Customs valuation and description of the goods. |
| Swissmedic establishment licence reference | Evidence the importer is authorised to import and distribute. |
| Marketing authorisation or trial reference | Shows the product is authorised or moving under a defined exemption. |
| GMP evidence or batch certificate | Batch release documentation, recognised under the EU MRA where applicable. |
| Temperature record | Proof the cold chain held, for temperature-sensitive products. |
| Dangerous-goods declaration | Required for dry ice, certain biologicals and other regulated goods. |
Clinical trial material
Import of investigational medicinal product for a Swiss clinical trial is tied to the trial authorisation. A trial needs approval from Swissmedic and the relevant cantonal ethics committee before material moves. The importing party still needs the appropriate establishment licence, and the IMP must be released and labelled for the trial. Because Basel, Zurich and Geneva host so many trials, the clinical corridor into Switzerland is busy and inspectors expect clean accountability from import through to site delivery and return.
Cold chain and special categories
- Cold chain. Many Swiss-bound shipments are frozen or refrigerated biologics. Expect to show continuous temperature data and a documented response to any excursion.
- Narcotics and controlled substances. These require a separate Swissmedic narcotics authorisation on top of the establishment licence.
- Dangerous goods. Dry ice and certain biological materials are regulated for transport and need the correct declaration and packaging.
Where shipments get held up
- 1The Swiss importer does not hold the correct Swissmedic establishment licence for the product category.
- 2Batch or GMP documentation is missing or does not match the consignment, so the goods cannot be released.
- 3Temperature data has a gap, forcing a quality decision before the product can be used.
- 4Customs classification or valuation on the invoice is wrong, delaying clearance.
- 5Controlled-substance or dangerous-goods paperwork is incomplete.
Frequently asked questions
The Swiss entity importing and distributing the product needs a Swissmedic establishment licence covering import and wholesale for that product category, with a Responsible Person accountable for GDP. The product must also be authorised for the Swiss market or move under a defined exemption such as a clinical trial.